… We have investigated the use of MMP11 as target for cancer immunotherapy. We used
im injection of plasmid DNA encoding mouse MMP11 derivatives, followed by DNA …

… cancer. We tested the ability of the gene product (WT1) to serve as a target antigen for tumor
–specific immunotherapy … The WT1 protein has been identified as a novel tumor antigen and …

… specific for viral antigens that lyse target cells by antigen recognition … antigen MUC1, due
to its expression in so many cancers, is sure to play a significant role in cancer immunotherapy …

… of cancer immunotherapy on more specifically targeted methods … Promising immunotherapies
based on recombinant and … mAbs that target antigens on the surface of cancer cells such …

… Monoclonal antibodies that target other tumour stromal and … The rationale for this targeted
cancer immunotherapy strategy … kill tumour cells expressing the tumour antigens. Therapeutic …

… defined target antigens with a synchronized cytokine pattern and being amenable to
large scale pharmaceutical manufacturing process) are warranted for vaccine development [43]. …

… Thus, until now mainly tumor-associated shared antigens have been targeted by active
and passive cancer immunotherapy (notable exceptions are discussed by Schmidt et al., this …

… loss of targeted antigens attenuate targeted immunotherapy. … Although these antibodies are
commonly used in the clinic … by the tumor, and loss of the targeted antigens due to the built-in …

… -targeted antibodies), and the use of antibodies against immune-checkpoint molecules such
as CTLA-4 and PD1. This review summarizes the main strategies in cancer immunotherapy …

… targeted immunotherapy, highlighting the progress and pitfalls of current CTAs-targeted cancer
immunotherapy… opportunity that CTAs-based cancer immunotherapy presents. Finally, we …